Study of the P16 Gene as a Predictor of Myelosuppression in Breast Cancer Patients
This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
UNC Lineberger Comprehensive Cancer Center
First received: February 17, 2011
Last updated: February 26, 2014
Last verified: February 2014
The primary purpose of this study is to measure the association between baseline expression of the senescence effector protein p16INK4a and myelosuppression due to chemotherapy in patients with breast cancer. Patients with Stage I-IV breast cancer will be included and myelosuppression will be assessed after the first cycle of chemotherapy via measurement of an absolute neutrophil count (ANC) measured one time between days 7-11 post cycle one. Study subjects will also be asked to complete a brief health behaviors questionnaire to gather information on other relevant variables.
||Observational Model: Case-Only
Time Perspective: Prospective
||LCCC 1027: Expression Of P16INK4a As A Predictor Of Myelosuppression In Patients With Breast Cancer
Primary Outcome Measures:
Biospecimen Retention: Samples With DNA
Secondary Outcome Measures:
- Define the Association Between p16INK4a Expression and Physical Activity, Smoking and Alcohol Consumption in Women with Breast Cancer Receiving Chemotherapy [ Time Frame: 24 months ] [ Designated as safety issue: No ]
To explore the associations between p16INK4a expression at baseline and amount of vigorous physical activity, smoking habits, and weekly alcohol consumption.
- Explore the Associations between p16INK4a Expression at Baseline and Other Chemotherapy-Related Toxicities including Nausea and Vomiting, Neuropathy, Fatigue and Other Grade 3 and 4 Toxicities [ Time Frame: 24 Months ] [ Designated as safety issue: No ]
To explore the associations between p16INK4a expression at baseline and other chemotherapy-related toxicities, including the maximum toxicity experienced during that course of chemotherapy.
- Explore Associations between p16INK4a Expression at Baseline, Chemotherapy Regimen, and its Effect on Patient Function [ Time Frame: 24 months ] [ Designated as safety issue: No ]
To explore the associations between p16INK4a expression at baseline and type of chemotherapy received, co-morbidities, concomitant medications, and tumor characteristics.
| Estimated Enrollment:
| Study Start Date:
| Estimated Study Completion Date:
| Primary Completion Date:
||December 2013 (Final data collection date for primary outcome measure)
|Ages Eligible for Study:
||18 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
Breast cancer patients at UNC North Carolina Cancer Hospital and other participating sights.
- ≥ 18 years of age;
- Histologically confirmed Stage I-IV breast cancer;
- ECOG Performance Status 0-3;
- Scheduled to start a new course of chemotherapy in the neo-adjuvant, adjuvant or metastatic setting for newly diagnosed or recurrent disease;
- Growth factors, e.g., filgrastim, pegfilgrastim, are allowed, but their dose and duration will be tracked.
- Absolute Lymphocyte Count (ALC) > 500 cells/μL as determined by routine CBC with differential;
- Signed, IRB approved written informed consent.
- Presence of acute, active infection;
- History of clonal bone marrow disorder (i.e., myelodysplastic or myeloproliferative disorder, acute or chronic leukemia);
- Other co-morbid illness which would impair ability to participate in the study;
- Concurrent experimental therapy (Note: concurrent biologic therapy IS permitted, provided it is not experimental).
- Prior or current receipt of histone deacetylase (HDAC) inhibitors
Please refer to this study by its ClinicalTrials.gov identifier: NCT01305954
|University of North Carolina
|Chapel Hill, North Carolina, United States, 27599 |
UNC Lineberger Comprehensive Cancer Center
||Hyman Muss, MD
||University of North Carolina
No publications provided
||UNC Lineberger Comprehensive Cancer Center
History of Changes
|Other Study ID Numbers:
|Study First Received:
||February 17, 2011
||February 26, 2014
||United States: Institutional Review Board
Keywords provided by UNC Lineberger Comprehensive Cancer Center:
North Carolina Cancer Hospital
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on March 10, 2014
Neoplasms by Site